Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 293

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study

Open access
Hochhaus, A, Masszi, T, Giles, F J, Radich, J P, Ross, D M, Gómez Casares, M T, Hellmann, A, Stentoft, J, Conneally, E, García-Gutiérrez, V, Gattermann, N, Wiktor-Jedrzejczak, W, le Coutre, P D, Martino, B, Saussele, S, Menssen, H D, Deng, W, Krunic, N, Bedoucha, V, Saglio, G·2017·Leukemia

Abstract

The single-arm, phase 2 ENESTfreedom trial assessed the potential for treatment-free remission (TFR; i.e., the ability to maintain a molecular response after stopping therapy) following frontline nilotinib treatment. Patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase with MR 4.5 ( BCR-ABL1 ⩽ 0.0032% on the International Scale ( BCR-ABL1 IS )) and ⩾ 2 years of frontline nilotinib therapy were enrolled. Patients with sustained deep molecular response during the 1-year nilotinib consolidation phase were eligible to stop treatment and enter the TFR phase. Patients with loss of major molecular response (MMR; BCR-ABL1 IS ⩽ 0.1%) during the TFR phase reinitiated nilotinib. In total, 215 patients entered the consolidation phase, of whom 190 entered the TFR phase. The median duration of nilotinib before stopping treatment was 43.5 months. At 48 weeks after stopping nilotinib, 98 patients (51.6%; 95% confidence interval, 44.2–58.9%) remained in MMR or better (primary end point). Of the 86 patients who restarted nilotinib in the treatment reinitiation phase after loss of MMR, 98.8% and 88.4%, respectively, regained MMR and MR 4.5 by the data cutoff date. Consistent with prior reports of imatinib-treated patients, musculoskeletal pain-related events were reported in 24.7% of patients in the TFR phase (consolidation phase, 16.3%).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/leu.2017.63

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 293

Metadata

Authors
Hochhaus, A., Masszi, T., Giles, F. J., Radich, J. P., Ross, D. M., Gómez Casares, M. T., Hellmann, A., Stentoft, J., Conneally, E., García-Gutiérrez, V, Gattermann, N., Wiktor-Jedrzejczak, W., le Coutre, P. D., Martino, B., Saussele, S., Menssen, H. D., Deng, W., Krunic, N., Bedoucha, V, & Saglio, G.
Venue
Leukemia
Published
2017-02-20
Volume
31
Issue
7
Pages
1525-1531
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
OpenAlex
W2590307110
Cited by
293
References
23
FWCI
26.60
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. https://app.cochat.ai/papers/10.1038/leu.2017.63
The paper
Hochhaus, A., Masszi, T., Giles, F. J., Radich, J. P., Ross, D. M., Gómez Casares, M. T., Hellmann, A., Stentoft, J., Conneally, E., García-Gutiérrez, V, Gattermann, N., Wiktor-Jedrzejczak, W., le Coutre, P. D., Martino, B., Saussele, S., Menssen, H. D., Deng, W., Krunic, N., Bedoucha, V, & Saglio, G. (2017). Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. https://doi.org/10.1038/leu.2017.63

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.